Ann-Christin Wendeln

Ann-Christin Wendeln

Auto-generated profile, based on publicly available information

Ann-Christin Wendeln

German Center for Neurodegenerative Diseases (DZNE) Tübingen Germany

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2018 in Nature
Verified
Journal Article
Closed access
PDF file
AWAnn-Christin Wendeln
Ann-Christin Wendeln
KDKaroline Degenhardt
Karoline Degenhardt
Lalit KauraniLalit Kaurani
Lalit Kaurani
MGMichael Gertig
Michael Gertig
TUThomas Ulas
Thomas Ulas
JNJonas J. Neher
Jonas J. Neher

28 August 2017 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
PFPetra Füger
Petra Füger
JHJasmin K Hefendehl
Jasmin K Hefendehl
KVKarthik Veeraraghavalu
Karthik Veeraraghavalu
AWAnn-Christin Wendeln
Ann-Christin Wendeln
CSChristine Schlosser
Christine Schlosser
MJMathias Jucker
Mathias Jucker

31 January 2019 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
MNMichael R. Nichols
Michael R. Nichols
MSMarie‐Kim St‐Pierre
Marie‐Kim St‐Pierre
AWAnn‐Christin Wendeln
Ann‐Christin Wendeln
NMNyasha J. Makoni
Nyasha J. Makoni
LGLisa K. Gouwens
Lisa K. Gouwens
CCColin K. Combs
Colin K. Combs
This review discusses the profound connection between microglia, neuroinflammation, and Alzheimer's disease (AD). Theories have been postulated, tested, and modified over several decades. The findings have further bolstered the belief that microglia‐mediated inflammation is both a product and contributor to AD pathology and progression. Distinct microglia phenotypes and their function, microglial recognition and response to protein aggregates in AD, and the overall role of microglia in AD are areas that have received considerable research attention and yielded significant results. The following article provides a historical perspective of microglia, a detailed discussion of multiple microglia phenotypes including dark microglia, and a review of a number of areas where microglia intersect with AD and other pathological neurological processes. The overall breadth of important discoveries achieved in these areas significantly strengthens the hypothesis that neuroinflammation plays a key role in AD. Future determination of the exact mechanisms by which microglia respond to, and attempt to mitigate, protein aggregation in AD may lead to new therapeutic strategies. image

10 October 2013 in Blood
Verified
Journal Article
Closed access
PDF file
KCKatrin J. Czogalla
Katrin J. Czogalla
Arijit BiswasArijit Biswas
Arijit Biswas
AWAnn-Christin Wendeln
Ann-Christin Wendeln
PWPhilipp Westhofen
Philipp Westhofen
CMClemens R. Müller
Clemens R. Müller
JOJohannes Oldenburg
Johannes Oldenburg
Since the discovery of warfarin-sensitive vitamin K 2,3-epoxide reductase complex subunit 1 (VKORC1), 26 human VKORC1 (hVKORC1) missense mutations have been associated with oral anticoagulant resistance (OACR). Assessment of warfarin resistance using the “classical” dithiothreitol-driven vitamin K 2,3-epoxide reductase (VKOR) assay has not reflected clinical resistance phenotypes for most mutations. Here, we present half maximal inhibitory concentrations (IC50) results for 21 further hVKORC1 mutations obtained using a recently validated cell-based assay (J Thromb Haemost 11(5):872). In contrast to results from the dithiothreitol-driven VKOR assay, all mutations exhibited basal VKOR activity and warfarin IC50 values that correspond well to patient OACR phenotypes. Thus, the present assay is useful for functional investigations of VKORC1 and oral anticoagulant inhibition of the vitamin K cycle. Additionally, we modeled hVKORC1 on the previously solved structure of a homologous bacterial enzyme and performed in silico docking of warfarin on this model. We identified one binding site delineated by 3 putative binding interfaces. These interfaces comprise linear sequences of the endoplasmic reticulum–lumenal loop (Ser52-Phe55) and the first (Leu22-Lys30) and fourth (Phe131-Thr137) transmembrane helices. All known OACR-associated hVKORC1 mutations are located in or around these putative interfaces, supporting our model. Key Points In vitro analysis of VKORC1 mutations perfectly reflects patients’ warfarin resistance phenotypes. In silico docking of warfarin on a VKORC1 model reveals a putative docking site in agreement with the locations of OACR-associated mutations.

7 December 2020 in Alzheimer's & Dementia
Verified
Journal Article
Open access
PDF file
LSLisa Steinbrecher
Lisa Steinbrecher
AWAnn‐Christin Wendeln
Ann‐Christin Wendeln
DBDesirée Brösamle
Desirée Brösamle
PLPing Liu
Ping Liu
KWKatleen Wild
Katleen Wild
JNJonas J. Neher
Jonas J. Neher
Background: Microglial cells play an important role in the pathogenesis of Alzheimer’s disease. We have previously shown that microglia activate the Hypoxia inducible factor‐1α (HIF‐1α) signalling pathway in response to cerebral β‐amyloidosis in a mouse model of Alzheimer’s pathology (Wendeln et al., Nature, 2018). Importantly, we also found that activation of microglial HIF‐1α signalling correlated with disease severity and that HIF‐1α levels were particularly elevated in plaque‐associated microglia.Method: In the experiments presented here, we analyzed the role of microglial HIF‐1α in promoting cerebral β‐amyloidosis by characterizing pathological hallmarks and microglial activation states in two APP transgenic mouse models with an induced HIF‐1α knockout (KO) in microglia cells.Result: Our results indicate that the lack of HIF‐1α in microglia increases their clustering around amyloid‐β plaques and alters the microglial phenotype and brain inflammatory state. While plaque load was indistinguishable in mice with/out microglial HIF‐1α, our data indicate that the increase in plaque‐associated microglia limits plaque‐induced neuronal damage.Conclusion: Our data indicate that HIF‐1α inhibition alters the microglial phenotype, leading to an increased number of microglia around amyloid‐β plaques, thereby protecting neurons.

1 November 2014 in Cytokine
Verified
Journal Article
Closed access
MHMeng-Ping M.P. Hsu
Meng-Ping M.P. Hsu
SDStephanie L.A. Drake
Stephanie L.A. Drake
AWAnn-Christin Wendeln
Ann-Christin Wendeln
RFRicardo Fraustro
Ricardo Fraustro
SRStefan Rose-John
Stefan Rose-John
ICIain L. Campbell
Iain L. Campbell